Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (E-1693)(COMPLETED) (STEP)

This study has been completed.
Sponsor:
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00431431
First received: February 2, 2007
Last updated: October 2, 2009
Last verified: October 2009
  Purpose

Both tibolone and raloxifene have been demonstrated to prevent postmenopausal bone loss. During treatment with tibolone bone mineral density (BMD) of the spine has been shown to be increased between 1.8 and 5.8 % above baseline in two years, depending on the population studied. Since treatments aimed at prevention should ideally be used long-term, compliance with the treatment is crucial. Efficacy of and compliance with the two treatments will be measured and evaluated.


Condition Intervention Phase
Osteopenia
Drug: tibolone
Drug: raloxifen
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by Schering-Plough:

Primary Outcome Measures:
  • Measure BMD to evaluate the effects of treatment on bone mineral density of the lumbar vertebrae L1-L4 [ Time Frame: At screening, after 52 weeks and 104 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To measure the effects on hot flushes by using diary booklets [ Time Frame: Throughout trial and up to week 52 ] [ Designated as safety issue: No ]
  • To measure the economic impact during the whole trial period by using Medical resource utilization forms [ Time Frame: Baseline and week 52 and 104 ] [ Designated as safety issue: No ]
  • Bone mineral density of the total hip [ Time Frame: At screening, week 52 and week 104 ] [ Designated as safety issue: No ]
  • A vaginal smear to determine vaginal atrophy [ Time Frame: At screening, week 52 and week 104 ] [ Designated as safety issue: No ]
  • Biochemical markers of bone metabolism [ Time Frame: At baseline, week 12, week 24, week 52 and week 104 ] [ Designated as safety issue: No ]
  • McCoy Female Sexuality Questionnaire, Short -Form to assess sexual functioning, Women's Health Questionnaire to assess quality of life, Health Utility Index Mark 2 and 3 (HUI2/HUI3) to confirm the health status [ Time Frame: At baseline, week 12, week 24, week 52 and week 104 ] [ Designated as safety issue: No ]

Enrollment: 324
Study Start Date: October 2000
Study Completion Date: February 2005
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
tibolone
Drug: tibolone
2 years treatment with tibolone (1.25 mg Org OD-14)
Active Comparator: 2
raloxifene
Drug: raloxifen
2 years treatment with raloxifene (60 mg)

  Eligibility

Ages Eligible for Study:   60 Years to 79 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Only subjects who give voluntary written informed consent, and who are willing and able to make reasonable efforts to observe all clinical trial requirements are to be enrolled.
  • Subjects will be osteopenic but otherwise healthy postmenopausal women, from 60 to 79 years of age (inclusive) at entry.
  • Screening BMD of the lumbar vertebrae (L1-L4) must be between -2.5 SD and

    • 1.0 SD of the T-score.
  • Subjects should have a Body Mass Index (BMI) >19 and < 30 kg/m2.

Exclusion Criteria:

  • Spinal X -ray with symptomatic vertebral fracture (more than 20% reduction in expected vertebral height).
  • History of bilateral hip replacements.
  • Subjects who are not ambulatory.
  • History or presence of any malignancy, except non-melanoma skin cancers.
  • TVUS double wall thickness > 4 mm, or any other undiagnosed abnormalities visualized by TVUS.
  • Abnormal cervical Pap smear result
  • Undiagnosed abnormal (in the investigator's opinion) vaginal bleeding in the past year prior to screening.
  • Mammography or physical examination finding that is suspicious of malignancy.
  • Uncontrolled hypertension
  • Bone disease other than osteoporosis such as Paget's disease, osteomalacia or bone metastases.
  • Drinking more than 4 glasses of alcohol containing drinks per day.
  • Smoking more than 20 cigarettes a day.
  • Current or recent prolonged use of hepatic microsomal enzyme-inducing anticonvulsant medication or other drugs known to interfere with or otherwise alter the pharmacokinetics of steroids.
  • Treatment with anabolic steroids, calcitonin or raloxifene within the last 6 months.
  • Treatment with alendronate and risedronate more than 6 months. If treatment duration was less than 6 months a wash-out period of 12 months is necessary.
  • Treatment with etidronate for 1 year a wash-out period of 6 months is necessary. If treatment period of more than 1 year a wash -out period of 12 months is necessary.
  • Treatment with oral estrogen and/or progestin therapy (including contraceptives) or transdermal therapy and local estrogen applications within 6 months prior to screening/baseline BMD measurements (i.e. the wash -out period of 6 months must have been completed before the screening / baseline BMD assessments are made). A 20-week wash-out for injections of MPA-containing contraceptives (e.g. Depo-Provera®) is required.
  • Ever use of estrogen and/or progestin containing implants.
  • The use of cholesterol-lowering medicine cholestyramine or colestipol.
  • Subjects with a change in thyroid medication within the last 6 weeks prior to screening.
  • Subjects who have had fluoride treatment for 2 weeks or more (> 2 mg/day fluorideion) at any time (NaF tablets for caries prevention is allowed).
  • Subjects who have undergone systemic glucocorticoid treatment (> 5 mg prednisone or equivalent/day) for more than one month within the past 6 months (prior to BMD screening assessments).
  • Subjects who are receiving or require medication for the treatment of osteoporosis except Calcium / Vit D.
  • The use of coumarin products.
  • Type I diabetes mellitus.
  • Presence or history of thromboembolic disorders.
  • Serious decompensated renal or liver disease.
  • Abnormal laboratory values
  • Any condition or disease that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
ClinicalTrials.gov Identifier: NCT00431431     History of Changes
Other Study ID Numbers: E-1693
Study First Received: February 2, 2007
Last Updated: October 2, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Tibolone
Raloxifene
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Modulators
Anabolic Agents
Hormones
Selective Estrogen Receptor Modulators
Bone Density Conservation Agents
Estrogen Antagonists

ClinicalTrials.gov processed this record on April 17, 2014